Literature DB >> 20570401

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.

Duygu Tosun1, Norbert Schuff, Diana Truran-Sacrey, Leslie M Shaw, John Q Trojanowski, Paul Aisen, Ronald Peterson, Michael W Weiner.   

Abstract

Previously it was reported that Alzheimer's disease (AD) patients have reduced beta amyloid (Abeta(1-42)) and elevated total tau (t-tau) and phosphorylated tau (p-tau(181p)) in the cerebrospinal fluid (CSF), suggesting that these same measures could be used to detect early AD pathology in healthy elderly individuals and those with mild cognitive impairment (MCI). In this study, we tested the hypothesis that there would be an association among rates of regional brain atrophy, the CSF biomarkers Abeta(1-42), t-tau, and p-tau(181p) and apolipoprotein E (ApoE) epsilon4 status, and that the pattern of this association would be diagnosis-specific. Our findings primarily showed that lower CSF Abeta(1-42) and higher tau concentrations were associated with increased rates of regional brain tissue loss and the patterns varied across the clinical groups. Taken together, these findings demonstrate that CSF biomarker concentrations are associated with the characteristic patterns of structural brain changes in healthy elderly and mild cognitive impairment subjects that resemble to a large extent the pathology seen in AD. Therefore, the finding of faster progression of brain atrophy in the presence of lower Abeta(1-42) levels and higher tau levels supports the hypothesis that CSF Abeta(1-42) and tau are measures of early AD pathology. Moreover, the relationship among CSF biomarkers, ApoE epsilon4 status, and brain atrophy rates are regionally varying, supporting the view that the genetic predisposition of the brain to beta amyloid and tau mediated pathology is regional and disease stage specific. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570401      PMCID: PMC2902689          DOI: 10.1016/j.neurobiolaging.2010.04.030

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  67 in total

1.  Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls.

Authors:  Jonathan H Morra; Zhuowen Tu; Liana G Apostolova; Amity E Green; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Arthur W Toga; Clifford R Jack; Norbert Schuff; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2008-11-08       Impact factor: 6.556

2.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

3.  Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.

Authors:  I Skoog; P Davidsson; O Aevarsson; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Dement Geriatr Cogn Disord       Date:  2003       Impact factor: 2.959

4.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Authors:  Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow
Journal:  Clin Chem       Date:  2004-11-24       Impact factor: 8.327

5.  Differential CSF biomarker levels in APOE-epsilon4-positive and -negative patients with memory impairment.

Authors:  Christin Andersson; Kaj Blennow; Sven-Erik Johansson; Ove Almkvist; Peter Engfeldt; Maria Lindau; Maria Eriksdotter-Jönhagen
Journal:  Dement Geriatr Cogn Disord       Date:  2006-11-22       Impact factor: 2.959

6.  Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging.

Authors:  Gaël Chetelat; Jean-Claude Baron
Journal:  Neuroimage       Date:  2003-02       Impact factor: 6.556

7.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

8.  Morphometric changes in the episodic memory network and tau pathologic features correlate with memory performance in patients with mild cognitive impairment.

Authors:  A M Fjell; K B Walhovd; I Amlien; A Bjørnerud; I Reinvang; L Gjerstad; T Cappelen; F Willoch; P Due-Tønnessen; R Grambaite; A Skinningsrud; V Stenset; T Fladby
Journal:  AJNR Am J Neuroradiol       Date:  2008-06       Impact factor: 3.825

9.  Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.

Authors:  William E Klunk; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Brian J Lopresti; Scott K Ziolko; Wenzhu Bi; Jessica A Hoge; Ann D Cohen; Milos D Ikonomovic; Judith A Saxton; Beth E Snitz; Daniel A Pollen; Majaz Moonis; Carol F Lippa; Joan M Swearer; Keith A Johnson; Dorene M Rentz; Alan J Fischman; Howard J Aizenstein; Steven T DeKosky
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

10.  Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI.

Authors:  Rachael I Scahill; Jonathan M Schott; John M Stevens; Martin N Rossor; Nick C Fox
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

View more
  50 in total

Review 1.  The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 2.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

3.  Toward a multifactorial model of Alzheimer disease.

Authors:  Martha Storandt; Denise Head; Anne M Fagan; David M Holtzman; John C Morris
Journal:  Neurobiol Aging       Date:  2012-01-20       Impact factor: 4.673

4.  Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.

Authors:  Charles B Malpas; Michael M Saling; Dennis Velakoulis; Patricia Desmond; Terence J O'Brien
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade.

Authors:  Nikki H Stricker; Hiroko H Dodge; N Maritza Dowling; S Duke Han; Elena A Erosheva; William J Jagust
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

6.  Longitudinal change of biomarkers in cognitive decline.

Authors:  Raymond Y Lo; Alan E Hubbard; Leslie M Shaw; John Q Trojanowski; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust
Journal:  Arch Neurol       Date:  2011-06-13

7.  Accelerating cortical thinning: unique to dementia or universal in aging?

Authors:  Anders M Fjell; Lars T Westlye; Håkon Grydeland; Inge Amlien; Thomas Espeseth; Ivar Reinvang; Naftali Raz; Anders M Dale; Kristine B Walhovd
Journal:  Cereb Cortex       Date:  2012-12-12       Impact factor: 5.357

8.  BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.

Authors:  Boris Decourt; Amanda Gonzales; Thomas G Beach; Michael Malek-Ahmadi; Aaron Walker; Lucia Sue; Douglas G Walker; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2013-03       Impact factor: 3.498

9.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

Review 10.  What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus.

Authors:  Anders M Fjell; Linda McEvoy; Dominic Holland; Anders M Dale; Kristine B Walhovd
Journal:  Prog Neurobiol       Date:  2014-02-16       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.